Alvogen Issues Voluntary Nationwide Recall of Clindamycin Injection Due to a Potential for a Lack of Sterility Assurance

Alvogen is voluntarily recalling seven lots of Clindamycin Injection USP ADD-Vantage Vials to the hospital/retail level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the product. Clindamycin Injection is manufactured for Alvogen by Hospira Inc., a Pfizer Company.

In the event that impacted product is administered, there is a reasonable probability that the patient may experience adverse events, ranging from fever, chills and malaise, to severe adverse events including systemic invasive mycoses or systemic bacterial sepsis. The possibility of a breach in sterility assurance in distributed product, while remote, cannot be eliminated. To date, Alvogen has not received any reports of adverse events associated with use of the product.

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible bacteria. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate.

Alvogen is notifying its distributors and customers via an Urgent Drug Recall Notice and is arranging for return of all recalled products. Anyone with existing inventory is requested to stop use and further distribution of the impacted lots, and quarantine the product immediately.

Any questions should be directed to Alvogen Customer Service at (844) 842-8672. For Medical related questions, contact Alvogen at (866) 770-3024. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product. For complete lot information, check the safety recall information on the FDA website.

  • <<
  • >>

Comments